

## NON-INVASIVE THERAPIES FOR MANAGEMENT OF TEMPOROMANDIBULAR DISORDERS: A SYSTEMATIC REVIEW

Fernanda Thomé Brochado<sup>1</sup>, Luciano Henrique de Jesus<sup>1</sup>,  
Manoela Domingues Martins<sup>1,2</sup>, Karen Dantur Chaves<sup>3</sup>,

Clin Biomed Res. 2019;39(3):238-243

1 Departamento de Patologia Oral,  
Faculdade de Odontologia, Universidade  
Federal do Rio Grande do Sul (UFRGS).  
Porto Alegre, RS, Brasil.

2 Departamento de Medicina Oral, Hospital  
de Clínicas de Porto Alegre (HCPA).  
Porto Alegre, RS, Brasil.

3 Departamento de Odontologia  
Conservadora, Faculdade de  
Odontologia, Universidade Federal do  
Rio Grande do Sul (UFRGS). Porto  
Alegre, RS, Brasil.

**Corresponding author:**

Manoela Domingues Martins  
manomartins@gmail.com  
Faculdade de Odontologia, Universidade  
Federal do Rio Grande do Sul (UFRGS)  
Rua Ramiro Barcelos, 2492, sala 503.  
90035-003, Porto Alegre, RS, Brasil.

### ABSTRACT

**Introduction:** As a multifactorial disease, temporomandibular disorders (TMD) require a complex therapeutic approach, being noninvasive therapies the first option for most patients. The aim of this study was to perform a systematic review to analyze the most common non-invasive therapies used for TMD management.

**Methods:** The review was done by searching electronic databases to identify controlled clinical trials related to pharmacologic and non-invasive treatments. Of all potential articles found, 35 were included in this review.

**Results:** Low-level laser therapy (LLLT), occlusal splints (OS) and oral exercises/behavior education (OE/BE) were the most common therapies used. LLLT showed significant results in pain and movement improvement in most studies. OS was usually combined to other therapies and resulted in improvement of pain. OE/BE showed significant results when combined with ultrasound, LLLT, and manual therapy.

**Conclusions:** Non-invasive treatments can provide pain relief and should be prescribed before surgical procedures. LLLT was the therapy with the higher number of studies showing positive results. Based in heterogeneity of treatment protocols, diagnostic and outcomes criteria used, new well-designed randomized controlled trials (RCT) are necessary.

**Keywords:** *Temporomandibular disorder; temporomandibular joint; myofascial pain; treatment; temporomandibular dysfunction; pharmacologic*

Temporomandibular disorders (TMD) are the most common chronic orofacial pain conditions. TMD include several clinical disabilities affecting the temporomandibular joint (TMJ) and masticatory muscles. Mainly characterized by pain, movement limitation, and TMJ sounds, TMD are usually associated with headache, cervical dysfunction, and other related signs and symptoms<sup>1-5</sup>. Pain is the most debilitating symptom, interfering with daily activities, quality of sleep, and psychological aspects as anxiety, stress, and depression<sup>6</sup>.

As multifactorial disorders, TMDs require a multidisciplinary approach. Usually, first treatment options are noninvasive treatments, including occlusal splint (OS), photobiomodulation (PBM), manual therapy (MT), electrotherapy, acupuncture, oral exercises and behavioral education therapies (OE/BE), as well as pharmacological therapy<sup>7-13</sup>. The primary goal of noninvasive therapies is pain relief, avoiding acute pain to become a chronic condition, which leads to changes of pain perception and delay of treatment responses<sup>4,6,10,14,15</sup>.

### **Occlusal splint (OS)**

Among management possibilities, OS is the most frequently recommended. OS is a removable appliance that covers all the occlusal and incisal surfaces of teeth in the upper or lower jaw<sup>6,10,11</sup>. Although the mode of action of OS is not fully clear, studies show that it promotes bilateral balancing and protects teeth

from wear caused by bruxism<sup>6,10,16</sup>. There are many types of OS with different indications and functions<sup>1,13,17</sup>. The most used are the stabilization splints, also known as Michigan splints. Usually made with hard acrylic, the splint is designed to provide a temporary and ideal occlusion leading to neuromuscular balance and decreasing muscle tension<sup>1,13,17,18</sup>.

#### **Low-level laser therapy (LLLT) – Photobiomodulation Therapy**

LLLT is the application of light within the red and near infra-red wavelength range of 600-1000 nm. It is a non-ablative and non-thermal light<sup>4,7,8,19</sup>, which has been widely used due its low cost, easy application, and short treatment time<sup>3</sup>. There is evidence that LLLT modulates the inflammatory process, reduces pain and edema, and increases blood circulation and extensibility of the nervous system<sup>4</sup>. In addition, no side effect is reported when correctly administered<sup>20</sup>. The clinical efficacy of TMD is controversial due to the difference in parameters, dosimetry, and assessment criteria used by studies, besides the clinical variability of TMD patients. For TMD symptoms, the commonly used wavelength is in the infrared spectrum from 780 nm to 904 nm<sup>3-7</sup>.

#### **Therapeutic ultrasound (US)**

US is the application of mechanical vibrations, known as sound energy, at increasing frequencies above 16 Hz generated by a piezoelectric effect using a frequency between 1.0 and 3.0 MHz. It is useful in fresh injuries with acute inflammation<sup>21,22</sup>. The right dosimetry ensures an optimal outcome with minimum risk of adverse effects<sup>21</sup>. Another useful application of ultrasound is in the administration of anti-inflammatory ointments with a hand-held transducer. The energy forces the diffusion of medications through the skin to target underneath soft tissues. This method is called phonophoresis<sup>21</sup>.

#### **Transcutaneous electrical nerve stimulation (TENS)**

Among therapies for TMD, TENS has been proposed as a safe and noninvasive therapy with low-voltage electrical pulses. Using electrodes on the skin over the painful area, TENS can modulate the control system of endogenous pain promoting pain relief and reduction of muscular activity<sup>6,22,23</sup>. There are two theories explaining its action on pain modulation. One theory suggests that the rhythmic contractions of muscles caused by TENS increase blood and lymph circulation, resulting in the decrease of interstitial swelling and improvement of the circulation of noxious tissue metabolites, leading to muscle relaxation<sup>22,24</sup>. The other theory is based on gate control, which preconizes that the electrical stimulus travels faster in afferent fibers of large diameters closing the pain gates of the spinal cord<sup>24</sup>.

#### **Manual therapy (MT)**

MT has been increasingly used due to the positive outcomes in some musculoskeletal and hypomobility conditions<sup>25,26</sup>. In masticatory muscles, MT promotes muscular relaxation, stimulates joint proprioception, relieves pain, and improves mandibular movements<sup>26</sup>. The literature reports that MT is an important method that promotes the release of opioid and non-opioid substances and inhibitory neurotransmitters that act in the central nervous system. Moreover, some studies suggest that MT can decrease the EMG activity in masticatory muscles<sup>26-28</sup>.

#### **Oral exercises and behavioral education (OE/BE)**

Self-management (SM) or self-care includes cognitive behavioral therapies as education about negative habits and counseling, relaxation techniques, and home exercises<sup>6</sup>. There is poor evidence of its effectiveness due to the differences on prescription<sup>12,29</sup>. Benefits of exercises include decrease in pain due to the release of endogenous non-opioid and opioid substances by stretching and strengthening masticatory muscles, increasing mobility, and tissue regeneration<sup>4-6,12,29</sup>. Stretching and relaxation exercises are first recommended when pain is present, helping patients to overcome the fear of moving the TMJ<sup>6,29</sup>. However, most studies compare these exercises with other therapies, which makes it difficult to evaluate the real effectiveness of this therapy alone<sup>25,29-31</sup>. While some studies indicate therapeutic exercises and BE as an essential part of treatment, others show the difficulties to define one program, since there is no established and tested gold standard for SM programs yet. In fact, previous studies present inconsistent results of therapeutic exercises and SM programs<sup>5,6,32</sup>.

#### **Acupuncture**

This millenary Chinese therapeutic method consists of placing needles into the skin for pain management. The technique uses specific acupoints and painful points. A variation of traditional acupuncture that has been widely used is dry needling, which applies needles with vigorous stimulation at trigger points<sup>33-35</sup>. Although several explanations are proposed, the mode of action is not fully clear. It is accepted that the needle penetration causes a micro-inflammation process improving blood circulation and neurotransmitters release, such as serotonin, enkephalin, and endorphin, which prevent the propagation of painful stimuli<sup>36-38</sup>. In addition, acupuncture promotes muscle relaxation, reestablishing body and mind balance, with recent studies showing benefits in anxiety, depression, and insomnia<sup>6,36,37</sup>. For TMD patients, acupuncture is suggested as an adjunctive and important method with positive effects such as decreased muscle tension and pain<sup>35</sup>.

### **Pharmacological treatments**

Pharmacological treatment is a common approach for orofacial pain as a monotherapy or associated with other therapies and surgical interventions. Used alone, it is considered a palliative therapy<sup>39,40</sup>. The most commonly used drugs to decrease pain and inflammatory process in joints and/or muscles are myorelaxants, non-steroidal anti-inflammatory drugs (NSAIDs), analgesics, tricyclic antidepressants (TCAs), benzodiazepines, and corticosteroids<sup>9,39,41</sup>. A wide range of pharmacotherapeutic agents is available; however, there is a lack of scientific evidence and no conclusive result for any of these drugs for the TMD population<sup>6,10,39,42</sup>.

Many clinical trials were performed with controversial results. Therefore, the main question of our review was: "Are non-invasive therapies effective to decrease pain and improve movements in TMD patients?"

## **METHODS**

### **Search strategy and inclusion criteria**

The bibliographical search was performed between January and August 2019. PubMed, Embase, and Scielo databases were used in two independent searches to identify relevant randomized clinical trials (RCTs) using non-invasive therapies in TMD patients, performed in the last 12 years. The first search used the keywords "*temporomandibular disorder*" OR "*temporomandibular joint*" AND "*myofascial pain*" AND "*treatment*". The second used the search terms "*temporomandibular dysfunction*" AND "*pharmacologic*". In addition, a hand search in the reference lists of included articles was done to identify other relevant studies and review articles.

### **Data collection and analysis**

Two reviewers independently identified titles and abstracts resulting from the search strategy for potentially eligible studies. Duplicate items were removed as well as studies with surgical intervention, invasive therapies, and rheumatic and neurologic diseases. Afterwards, a full text reading was performed for final eligibility.

### **Data extraction**

The data and results of each included study were extracted using a standard form. All data were cross-checked by a second reviewer. Any lack of agreement was resolved by discussion. The data analysis was based on the type of intervention and outcomes. The primary outcome of interest for this review was pain and the secondary outcome was range of motion (ROM).


### **Methodological quality assessment**

The Cochrane risk of bias tool<sup>43</sup> was used to assess the methodological quality of the studies according to the following domains: random sequence generation, allocation concealment, blinding, incomplete data, selective reporting and other potential sources of bias.

## **RESULTS**

### **Literature search**

The initial search found 517 articles about therapies and 128 articles about pharmacological treatments, resulting in 645 articles. Of these, 557 were excluded due to duplications, invasive therapies or surgical procedures, reviews, and case reports. A total of 82 articles were selected for full text reading (63 about therapies and 25 about pharmacological treatment) and finally 35 articles were included in this systematic review (Figure 1).



### Study characteristics and interventions

The main characteristics of the 35 included studies are described in Chart 1a and Chart 1b. The sample sizes ranged between 12 and 104 individuals with TMD symptoms, including men and women allocated in the same comparison group, except three studies that included only women<sup>4,44,45</sup>.

Of all the included studies, 13 (37%) used OS<sup>1,10,16,36,46-54</sup>, 12 (34%), OE/BE<sup>1,5,16,25,27,31,47,48,50-52,54</sup>, 12 (34%), LLLT<sup>2,5,15,20,24,44,55,57-60</sup>, 7 (20%), MT<sup>5,25,27,47,52,54,61</sup>, 4 (11%), acupuncture<sup>33,36,46,62</sup>, 3 (9%), NSAIDs<sup>10,44,53</sup>, 3 (9%), TENS<sup>22,24,54</sup>, 2 (6%), US<sup>22,31</sup>, one (3%)

benzodiazepine<sup>58</sup>, one (3%) TCAs and Gabapentin<sup>59</sup>, and one (3%), melatonin<sup>45</sup>.

Fourteen studies (40%) did not use control or placebo groups for comparison with the test therapy. The comparison of techniques using 2 or more groups was done in 30 (86%) studies<sup>2,5,10,24,33,44,45,54-59,61-63</sup>.

Risk of bias is shown in Chart 2. A total of 29 (82%) studies presented low risk<sup>1,2,5,10,15,16,20,24,25,27,31,33,36,45-48,50,51,54-59,61-64</sup> and three (9%) presented high risk<sup>44,49,61</sup>.

Other three (9%) studies showed an unclear risk of bias due to insufficient information in at least one domain<sup>22,52,53</sup>.

Chart 1a: Main characteristics of the included studies – Therapies

Study	Diagnostic Criteria	Outcomes	Groups	Location of application and type of exercises	Effects
Ismail et al., 2007	RDC/TMD VAS	Pain Mouth opening	Occlusal splint MT + OE + Occlusal splints	Muscles	Pain: significant decrease intragroup and no difference between the groups. Function: significant decrease intragroup and no difference between the groups.
Carrasco et al., 2008	VAS Palpation Colorimetric Method	Pain Mouth opening	LLLLT (780nm) LLLLT Placebo	Joint (5 points)	Pain: significant reduction in the LLLT group Function: No significant difference
Cuccia et al., 2009	VAS Calibrated caliper	Pain Mouth opening	Osteopathic manual therapy (OMT) Conventional conservative therapy (CCT)	Cervical and masticatory muscles	Pain: Significant difference intragroup in both groups. No significant difference between groups. Function: Significant difference intragroup in the OMT group. No significant difference between groups.
Felício et al., 2009	RDC/TMD Helkimo's Indexes ProTMDMulti protocol Orofacial Myofunctional Evaluation (OMES Protocol).	Pain Mandibular range of motion Function	Orofacial myofunctional therapy Occlusal splint Control TMD Control	Masticatory muscles Tongue	Pain: Significant reduction in the exercise group (intergroup) Function: Significant difference in the exercise group (intergroup)
Fernández-Camero et al., 2010	RDC/TMD VAS Algometer	Pain Mouth opening	Acupuncture Sham Acupuncture	Muscular pain points	Pain: significant difference Function: significant difference
Mazzeto et al., 2010	VAS Millimeter ruler	Pain Mouth opening	LLLLT (830 nm) LLLLT Placebo	Joint (4 points)	Pain: significant difference Function: significant difference
Kalamir et al., 2011	RDC/TMD Rating scale – 0-10	Pain Mouth opening	Manual therapy (IMT) OE + BE (ESC)	Intra oral masticatory muscles	Pain: significant reduction IMT group (intergroup) Function: no significant between groups
Vicente-Barrero et al., 2012	VAS Millimeter ruler pressure algometer	Pain Mouth opening	Acupuncture Occlusal splints	Acupoints	Pain: significant reduction myofascial pain in both groups. No significant reductions in subjective pain and pain on pressure points in occlusal splints. Function: significant improvements in the Acupuncture group. No significant difference between groups.

Continue...

Chart 1a: Continuation.

Study	Diagnostic Criteria	Outcomes	Groups	Location of application and type of exercises	Effects
Itoh et al., 2012	Palpation VAS Millimeter ruler	Pain Mouth opening	Acupuncture Sham Acupuncture	Masticatory and cervical muscles	Pain: significant reduction in both groups Function: no significant difference
Niemela et al., 2012	VAS Clinical examination	Pain Mouth opening	Occlusal splints OE/BE	Muscles	Pain: no significant difference between groups Function: no significant difference in between groups
Katyayan et al., 2014	RDC/TMD. VAS	Pain Mouth opening	Occlusal splints OE/BE	Muscles	Pain: no significant difference between groups Function: no significant difference in between groups
Grillo et al., 2015	RDC/TMD VAS Millimeter ruler digital algometer Pulsology and tongue observation	Pain Mouth opening	Acupuncture Occlusal splints	Acupoints Flat occlusal splint	Pain: significant reduction in both groups Function: significant increase in both groups
Michelotti et al., 2012	RDC/TMD. VAS	Pain Mouth opening	Occlusal splints Behavioral education (BE)	Muscles	Pain: significant reduction in the BE group Function: no significant difference
Qvintus et al., 2015	RDC/TMD. VAS	Pain Mouth opening	Occlusal splints Control – OE +BE	Muscles	Pain: no significant difference between groups. Function: no significant difference between groups
Ucar et al., 2014	RDC/TMD VAS Millimeter ruler	Pain Mouth opening	US + OE Control -OE	Muscles	Pain: significant reduction in both groups Function: significant reduction in both groups
Salmos-Brito et al., 2013	RDC/TMD VAS Millimeter ruler	Pain Mouth opening	LLLT (830 nm)	Joint (5 points)	Pain: no significant difference Function: significant increase in the acute group
Tuncer et al., 2013	VAS Millimeter ruler	Pain Mouth opening	OE/BE (HPT) Manual therapy + OE/BE (MT+HPT)	Muscles	Pain: significant decrease in the MT + HPT Function: significant improvement MT + HPT
Ahari et al., 2014	RDC/TMD VAS Millimeter ruler	Pain Mouth opening	LLLT (810 nm) Placebo	Muscular (pain)	Pain: significant decrease Function: significant improvement

Continue...

Chart 1a: Continuation.

Study	Diagnostic Criteria	Outcomes	Groups	Location of application and type of exercises	Effects
Sancakli et al., 2015	RDC/TMD VAS Algometer	Pain Mouth opening	LLLT (820 nm) – pain points LLLT (820 nm) – pre-established points	Masseter and temporalis. 3 points on the temporalis muscle.	Pain: significant reduction in both groups Function: significant reduction in both groups
Pereira et al., 2014	RDC/TMD Numerical rating scale	Pain Mouth opening	LLLT (660 nm) LLLT (795 nm)	Muscles and joint	Pain: significant reduction in the infrared group (180 days) Function: significant increase in the infrared group (180 days)
Rai et al., 2016	RDC/TMD VAS	Pain Mouth opening	Control US Tens	Muscles	Pain: significant decrease US Function: no significant improvement
Machado et al., 2016	RDC/TMD	Pain palpation Mouth opening	LLLT (780 nm) + OE (GI) Orofacial myofunctional therapy (GII) LLLT placebo + OE (GIII) LLLT (780 nm) (GIV) LLLT Placebo	5 points TMJ and painful muscles	Pain: significant reduction in the Combined, GII and GI groups Function: significant increase in the Combined, GII and GI groups
Grootel et al., 2017	RDC/TMD VAS	Pain Mouth opening	Occlusal splints OE	Muscles	Pain: no significant difference Function: no significant difference
Seifi et al., 2017	VAS Millimeter ruler	Pain Mouth opening	TENS LLLT (810 nm) Sham TENS Sham LLLT	Muscles	Pain: significant reduction on experimental groups. Function: significant improvement in the mouth opening on experimental groups.
Ferreira et al., 2016	RDC/TMD VAS Algometer Electromyography (EMG)	Pain Mouth opening	TENS TENS Placebo	Masticatory muscles	Pain: significant decrease Function: no significant difference

Continue...

Chart 1a: Continuation.

Study	Diagnostic Criteria	Outcomes	Groups	Location of application and type of exercises	Effects
Huttunen, et al., 2018	RDC /TMD (axis I and II) VAS Helkimo's Index	VAS Psychosocial effects	Splint Control group		Pain: No significant difference
Brochado et al., 2018	RDC/TMD VAS Beck inventory	Pain Range of motion Psychosocial effects	Manual Therapy LLLT (810 nm) Manual therapy + LLLT	Joint (5 points) Muscles	Pain: No significant difference between groups Function: No significant difference between groups
Borges et al., 2018	VAS Fonseca questionnaire Computerized biophotogrammetry	Pain Mobility	LLLT (830 nm) - 8 J/cm <sup>2</sup> LLLT (830 nm) - 60 J/cm <sup>2</sup> LLLT (830nm) - 105 J/cm <sup>2</sup> Control	Joint (4 points)	Pain: No significant difference between groups Function: Significant improvement in the 8 J/cm <sup>2</sup> MMO
Herpich et al., 2019	RDC/TMD VAS Digital Caliper Patient-Specific Functional Scale	Pain Mouth opening	Intraoral Laser (905 nm) + red LED (670 nm) + infrared LED (875 nm) Sham group	Intraoral	Pain: Significant difference in the treatment group after 48hs and 6 sessions Function: No significant difference between groups

Continue...



Chart 1b: Main characteristics of the included studies – Therapies.

Study	Diagnostic Criteria	Outcomes	Groups	Effects
Mejersjo et al, 2008	VAS Helkimo index	Pain	NSAID Occlusal splints	Pain: No significance between groups Significant reduction intragroup
Pramod et al, 2011	RDC/TMD VAS Millimeter ruler	Pain Tenderness Mouth opening	Benzodiazepine Placebo	Pain: no significant reduction intergroup Function: significant increase intergroup
Vidor et al, 2013	RDC/TMD VAS	Pain Sleep quality	Melatonin Placebo	Pain: significant reduction in the melatonin group
Varoli et al, 2015	RDC/TMD VAS	Pain	NSAID + Occlusal splints Occlusal splints Panacea + Occlusal splints	Pain: significant reduction in all groups. No significant reduction between the groups.
Haviv et al, 2015	Verbal pain Scale (VPS) RDC/TMD	Pain	TCAs GBP	Pain: significant reduction in both groups. In pain spread, GBP had significant better results.
Cavalcanti et al, 2016	Palpation Fonseca questionnaire	Pain	LLLT (780 nm) Myorelaxing drug +anti-inflammatory drug + OE + hot packs Placebo light	Pain: significant reduction in experimental groups

Chart 2: Risk of bias

	Random sequence generation	Allocation concealment	Blinding of patients, personnel	Blinding of outcome assessors	Incomplete outcome data	Selective outcome reporting	Other
Ismail et al., 2007	Green	Green	Red	Green	Green	Green	Green
Mejersjo et al., 2008	Green	Yellow	Yellow	Yellow	Red	Green	Green
Carrasco et al., 2008	Green	Green	Green	Green	Yellow	Green	Green
Cuccia et al., 2009	Yellow	Yellow	Yellow	Green	Red	Green	Green
Felicio et al., 2009	Green	Yellow	Red	Yellow	Green	Green	Green
Fernández-Camero et al., 2010	Green	Green	Green	Green	Green	Green	Green
Mazzeto et al., 2010	Yellow	Yellow	Green	Green	Red	Green	Green
Pramod et al., 2011	Green	Green	Green	Green	Green	Green	Green
Kalamir et al., 2011	Green	Green	Red	Green	Green	Green	Green
Itoh et al., 2012	Green	Green	Green	Green	Green	Green	Green
Vicente-Barreto et al., 2012	Yellow	Yellow	Red	Red	Green	Green	Green
Niemela et al., 2012	Green	Green	Red	Green	Green	Green	Green
Michelotti et al., 2012	Green	Green	Red	Green	Green	Green	Green
Vidor et al., 2013	Green	Green	Green	Green	Green	Green	Green
Salmos-Brito et al., 2013	Green	Green	Green	Green	Green	Green	Green
Tuncer et al., 2013	Green	Green	Red	Red	Green	Green	Green
Ahari et al., 2014	Green	Green	Green	Green	Green	Green	Green
Pereira et al., 2014	Green	Green	Green	Green	Green	Green	Green
Katyayan et al., 2014	Green	Green	Red	Yellow	Green	Green	Green
Ucar et al., 2014	Yellow	Yellow	Red	Red	Green	Green	Green
Grillo et al., 2015	Green	Green	Green	Green	Green	Green	Green
Sancakli et al., 2015	Green	Green	Green	Green	Green	Green	Green
Varoli et al., 2015	Green	Yellow	Green	Green	Yellow	Green	Green
Qvintus et al., 2015	Green	Green	Red	Yellow	Red	Green	Green
Haviv et al., 2015	Red	Red	Red	Red	Red	Red	Red
Machado et al., 2016	Green	Green	Green	Green	Green	Green	Green
Ferreira et al., 2016	Green	Green	Green	Green	Green	Green	Green
Cavalcanti et al., 2016	Red	Red	Green	Yellow	Yellow	Green	Red
Rai et al., 2016	Yellow	Yellow	Red	Green	Red	Green	Green
Grootel et al., 2017	Green	Green	Green	Green	Green	Green	Green
Seifi et al., 2017	Yellow	Yellow	Red	Green	Green	Green	Green
Huttunen et al., 2018	Yellow	Red	Red	Red	Red	Red	Green
Brochado et al., 2018	Green	Green	Red	Green	Green	Green	Green
Borges et al., 2018	Green	Green	Green	Yellow	Green	Green	Green
Herpich et al., 2019	Green	Green	Green	Green	Green	Green	Green

**Outcomes**

To assess the presence of TMD, as well as the type of disorder and diagnosis of myofascial pain, 24 (68%) studies applied the standardized evaluation protocol, the Research Diagnostic Criteria for Temporomandibular Disorders (RDC/TMD)<sup>1,2,5,10,15,16,20,22,27,31,45-49,50,54,56,58,61,62,64</sup>, three (9%)

used the Helkimo index<sup>49,53,54</sup>, and two (6%) applied the Fonseca questionnaire<sup>44,63</sup>. The remaining 8 (23%) studies adopted non-standard evaluation protocols, using clinical evaluation to include patients with signs and symptoms of TMD<sup>24,25,33,36,51,52,55,57</sup>.

All studies evaluated the outcomes at baseline and after the treatment protocol<sup>61</sup>, with number of sessions varying from 1 week to 1 year. Pain levels were assessed as the primary outcome in all studies using Visual Analogic Scale (VAS) in 29 (83%) studies<sup>1,2,10,15,16,22,24,25,31,33,36,45-59,61-64</sup> or an algometer to evaluate the pressure pain threshold in 5 (14%) studies<sup>2,36,46,58,62</sup>; one study (3%) used the Verbal Pain Scale<sup>59</sup>. The results of an intragroup analysis demonstrated that 27 (77%)<sup>5,10,20,22,24,25,27,31,33,36,44,45,46,47,50,52-63</sup> of the studies presented reduction in pain and 22 (62%)<sup>2,5,10,15,20,24,25,31,36,44-47,52-54,56,57,59,60,62,64</sup>, improvement in function. Among them, LLLT (34%)<sup>2,515,20,24,44,55-58,63,64</sup>, OE/BE (28%)<sup>5,16,21,25,27,47,48,50,51,54</sup>, and OS (31%)<sup>1,10,16,36,46-51,53,54</sup> were the most used. When analyzing the differences between treatments at the end of the protocols (intergroup analysis), 20 (57%) of the studies showed no significant difference in the levels of pain<sup>1,2,10,15,16,24,31,33,36,44,46-49,51-53,59,63,64</sup>.

In terms of secondary outcome measures, changes in mouth opening were evaluated in 29 (82%) studies. A millimeter ruler was used in 10 (29%) studies<sup>15,24,25,31,33,36,46,56,57,63</sup> and a caliper in 4 (11%)<sup>1,27,52,58</sup>. The remaining 6 (17%) studies did not describe the secondary outcome<sup>10,44,45,49,53,60</sup>. Significant improvement in mouth opening was described only in 13 (37%) studies using LLLT (17%)<sup>15,20,24,56,57,64</sup>, acupuncture (6%)<sup>36,62</sup>, MT (6%)<sup>25,52</sup>, TENS (3%)<sup>24</sup>, OMT (3%)<sup>54</sup>, and benzodiazepine (3%)<sup>59</sup>. The combination of MT and OE/BE (9%)<sup>5,25,54</sup> or LLLT and OE (3%)<sup>5</sup> had significantly better results than the therapies alone or placebo.

**DISCUSSION**

Non-invasive therapies have been recommended as first choice treatment for TMD arousing the interest of many authors who attempted to find a gold standard treatment protocol<sup>6,7</sup>. Despite the wide use of these therapies in clinical practice, the efficacy of most of them in TMD is still controversial, probably due to the variety of parameters and protocols<sup>7,60,65</sup>. Our results demonstrated that non-invasive therapies presented a low positive response, found in only 43% of the studies. Among them, OS, OE/BE and LLLT were the most commonly used. LLLT was the treatment with the highest rate of improved TMD symptoms. The absence of a placebo or a control group was noteworthy. The included RCTs had good methodological quality with low risk of bias.

The correct diagnostic of TMD is complex but essential to decide treatment strategies and follow

the patients. The diagnosis is usually based on validated questionnaires and clinical tests<sup>4,7</sup>. The RDC/TMD is one of the most used instruments which classified the types and subtypes of TMD (axis I) and information related to psychosocial aspects (axis II) of patients<sup>6,8</sup>. Our review showed that 24 (68%)<sup>1,2,5,10,15,16,20,22,27,31,45-49,50,54,56,58,61,62,64</sup> studies used a gold standard method (RDC/TMD-axis I) to diagnose TMD, which ensures a good analysis of the effects of therapies. Only few studies applied other validated index, such as Helkimo's<sup>49,53,54</sup> and Fonseca<sup>44,64</sup>, to assess the severity of TMD symptoms, but these questionnaires present some limitations and are not able to provide sufficient information to classify TMD dysfunction<sup>44,53,54</sup>. Besides that, our results showed only one study<sup>63</sup> that considered the psychosocial aspects and their influence on primary and secondary outcomes. TMD treatment has been considered a challenge because of its multifactorial origin, including a complex interaction among physical, behavioral, social, and psychological factors<sup>49,52,60</sup>. Based on these aspects, the analysis of the impact of treatment strategies based on the perspective of quality of life has been currently suggested. Therefore, new clinical trials involving TMD treatment should include Axis II of RDC and other questionnaires of anxiety and/or quality of life.

Pain is well known as the main symptom of TMD leading the patients to incapacity and a poor quality of life.<sup>7</sup> Corroborating with these, our review showed that all analyzed studies evaluated pain as the primary outcome. VAS was the most common strategy to evaluate the levels of pain in 29 (83%) studies<sup>1,2,10,15,16,22,24,25,31,33,36,45-53,55-59,61-64</sup>. Another important outcome observed in the studies analyzed was mouth opening<sup>2,5,10,15,20,24,25,31,36,44-47,52-54,56,57,59,60,62,64</sup>. This is an important aspect to be addressed because it can interfere with patient's daily activities such as chewing, oral hygiene, smiling and others.

Interestingly, results were observed regarding the effect of different non-invasive therapies especially evaluating pain (main outcome). Analyzing intragroup data, all therapies demonstrated positive effect to relieve pain comparing the baseline with the end of the treatment. However, the intergroup analysis (comparison among groups) does not demonstrate the same positive results. Only 15 (43%) of the 35 studies presented significant difference between groups. The LLLT presented better results in most of the studies evaluating pain (17%)<sup>5,20,55-58</sup> and range of movement (17%)<sup>2,15,20,56,57,59</sup>.

The interest on LLLT is increasing, since its application is easy with no reported side effects<sup>4</sup>. Different parameters, such as number of sessions, sites of application, and dosimetry have been described, which indicate that this is a controversial therapy<sup>3</sup>. Some authors believe that 8 sessions with applications twice

a week promote positive effects<sup>52,57</sup>. However, other authors<sup>2,5,15,56</sup> propose 12 sessions. In addition, two authors applied the therapy using 3<sup>20</sup> or 4 sessions<sup>24</sup> during only one week, although they found inconsistent results. LLLT application points also varied among studies, being the most common the jaw, masseter, temporalis, and pterygoid muscles (intraorally)<sup>2,56</sup>. Better results in pain and mobility were described using pre-established muscular points (masseter, temporalis, and pterygoid) or trigger points<sup>2</sup> rather than the joint points. In addition, the infrared laser provides better results in the long term (180 days) compared with red laser. However, short-term effects did not show statistical difference between red and infrared wavelengths<sup>20</sup>. One recent study<sup>64</sup>, compared different protocols of LLLT (830 nm) showing that 8J/cm<sup>2</sup> is more effective to improve mouth opening than 60 J/cm<sup>2</sup> or 105 J/cm<sup>2</sup>. However, all protocols of LLLT promoted pain relief.

The OS is widely recommended<sup>49</sup> and is one of the most used treatments in the RCTs included in the present review. However, the analysis of our results showed that its benefits in improving TMD symptoms are controversial<sup>6,49</sup> especially because OS had been used in combination with other therapies. Among the 12 studies that used OS<sup>1,10,16,36,46-51,53,54</sup>, only 4 (33%) used as an individual treatment option and showed reduction in pain<sup>36,46,49,54</sup>. The other studies compared the effects of OS with acupuncture<sup>36,46</sup>, Manual therapy<sup>55</sup> and/or NSAIDs<sup>10,53</sup> and showed improvement in pain in all different treatment groups. These results indicated that all of these treatments reduced pain and can be applied alone or in combination as good choice for TMD patients.

Another non-invasive therapy commonly used in our review was OE/BE. Like OS, OE/BE had been used in clinical trials mostly in combination with other therapies. In general, among the 10 studies included, 6 (60%) showed positive results with decrease of TMD symptoms<sup>5,25,27,50,52,54</sup>. It is difficult to compare the results among studies due to the differences in exercise protocols, time of duration of the treatment that varied from 10<sup>1,48,51</sup> to 45 min<sup>47</sup> and from 2 to 3 times/day<sup>1,31,48,51</sup> to 2 times/week<sup>25,47</sup>. Two studies used a very well-designed protocol called oral myofunctional therapy which combined BE instruction, oral, respiratory and cervical exercises with thermotherapy and self-massage. Both evidenced positive results in improvement of pain and masticatory function in OE/BE group<sup>5,54</sup>.

Pharmacological treatment is frequently recommended for orofacial pain<sup>42</sup>; however, we found only 6 (18%) RCTs using pharmacological treatments for TMD. Most of the existing literature evaluating pharmacologic treatments are observational clinical studies instead of RCTs<sup>40,59</sup>. The selected studies evaluated the effects of benzodiazepine (16%)<sup>59</sup>,

anti-inflammatory (33%)<sup>10,53</sup>, myorelaxant drugs (16%)<sup>44</sup>, melatonin (16%)<sup>45</sup>, and TCA and gabapentin (16%)<sup>60</sup>. Positive improvements were found only with melatonin<sup>45</sup>. Besides that, significant results for pain spread were found using gabapentin<sup>60</sup>. These results indicated that more clinical trials studies are necessary to evaluate the impact of pharmacological treatment in TMD patients.

## CONCLUSION

TMD is a complex musculoskeletal disorder with several clinical, psychological, and behavioral components, leading to a difficult standardization of

protocols and treatment evaluation. In this review, non-invasive therapies were the first choice for TMD patients and all of them improve, at least partially, TMD signs and symptoms. Therefore, noninvasive treatments can provide pain relief and should be prescribed before surgical procedures. LLLT, OS, OE/BE were the most commonly used therapies. LLLT was the therapy with the higher number of studies showing positive results compared to placebo, control, or other therapies. In general, important heterogeneity in treatment protocols, diagnostic and outcomes criteria was observed indicating the necessity of new well-designed randomized controlled trials.

## REFERENCES

- Katyayan PA, Katyayan MK, Shah RJ, Patel G. Efficacy of appliance therapy on temporomandibular disorder related facial pain and mandibular mobility: a randomized controlled study. *J Indian Prosthodont Soc.* 2014;14(3):251-61.
- Sancakli E, Gökçen-Röhlüg B, Balık A, Öngül D, Kıpırdı S, Keskın H. Early results of low-level laser application for masticatory muscle pain: a double-blind randomized clinical study. *BMC Oral Health.* 2015;15(1):131.
- Chen J, Huang Z, Ge M, Gao M. Efficacy of low-level laser therapy in the treatment of TMDs: a meta-analysis of 14 randomized controlled trials. *J Oral Rehabil.* 2015;42(4):291-9.
- Herpich CM, Amaral AP, Leal-Junior ECP, Tosato JP, Gomes CAF, Arruda ÉEC, et al. Analysis of laser therapy and assessment methods in the rehabilitation of temporomandibular disorder: a systematic review of the literature. *J Phys Ther Sci.* 2015;27(1):295-301.
- Machado BC, Mazzetto MO, Silva MA, Felício CM. Effects of oral motor exercises and laser therapy on chronic temporomandibular disorders: a randomized study with follow-up. *Lasers Med Sci.* 2016;31(5):945-54.
- List T, Jensen RH. Temporomandibular disorders: old ideas and new concepts. *Cephalalgia.* 2017;37(7):692-704.
- Maia ML, Bonjardim LR, Quintans JS, Ribeiro MAG, Maia LG, Conti PC. Effect of low-level laser therapy on pain levels in patients with temporomandibular disorders: a systematic review. *J Appl Oral Sci.* 2012;20(6):594-602.
- Rodrigues JH, Marques MM, Biasotto-Gonzalez DA, et al. Evaluation of pain, jaw movements, and psychosocial factors in elderly individuals with temporomandibular disorder under laser phototherapy. *Lasers Med Sci.* 2015;30(3):953-9.
- Wieckiewicz M, Boening K, Wiland P, Shiao Y-Y, Paradowska-Stolarz A. Reported concepts for the treatment modalities and pain management of temporomandibular disorders. *J Headache Pain.* 2015;16:106.
- Varoli FK, Pita MS, Sato S, Issa JPM, Nascimento C, Pedrazzi V. Analgesia evaluation of 2 NSAID drugs as adjuvant in management of chronic temporomandibular disorders. *Sci World J.* 2015:1-7. <http://dx.doi.org/10.1155/2015/359152>.
- Zhang C, Wu JY, Deng DL, He BY, Tao Y, Niu YM, Deng MH. Efficacy of splint therapy for the management of temporomandibular disorders: A meta-analysis. *Oncotarget.* 2016;7(51):84043-53.
- Dickerson SM, Weaver JM, Boyson AN, Thacker JA, Junak AA, Ritzline PD, Donaldson MB. The effectiveness of exercise therapy for temporomandibular dysfunction: a systematic review and meta-analysis. *Clin Rehabil.* 2017;31(8):1039-43.
- Pficer JK, Dodic S, Lazic V, Trajkovic G, Milic N, Milicic B. Occlusal stabilization splint for patients with temporomandibular disorders: meta-analysis of short and long-term effects. *PLoS One.* 2017;12(2):e0171296.
- Bouloux GF. Use of opioids in long-term management of temporomandibular joint dysfunction. *J Oral Maxillofac Surg.* 2011;69(7):1885-91.
- Salmos-Brito JA, Menezes RF, Teixeira CE, Gonzaga RK, Rodrigues BH, Braz R, et al. Evaluation of low-level laser therapy in patients with acute and chronic temporomandibular disorders. *Lasers Med Sci.* 2013;28(1):57-64.
- van Grootel RJ, Buchner R, Wismeijer D, van der Glas HW. Towards an optimal therapy strategy for myogenous TMD, physiotherapy compared with occlusal splint therapy in an RCT with therapy-and-patient-specific treatment durations. *BMC Musculoskelet Disord.* 2017;18(1):76.
- Ebrahim S, Montoya L, Busse JW, Carrasco-Labra A, Guyatt GH. The effectiveness of splint therapy in patients with temporomandibular disorders: a systematic review and meta-analysis. *J Am Dent Assoc.* 2012;143(8):847-57.
- Hasegawa Y, Kakimoto N, Tomita S, Fujiwara M, Ishikura R, Kishimoto H, Honda K. Clinical study of splint therapeutic efficacy for the relief of temporomandibular joint discomfort. *J Craniomaxillofacial Surg.* 2017;45(11):1772-7.
- Zecha JA, Raber-Durlacher JE, Nair RG, Epstein JB, Sonis ST, Elad S, et al. Low level laser therapy/photobiomodulation in the management of side effects of chemoradiation therapy in head and neck cancer: part 1: mechanisms

- of action, dosimetric, and safety considerations. *Support Care Cancer*. 2016;24(6):2781-92.
20. Pereira TS, Flecha OD, Guimarães RC, Oliveira D, Botelho AM, Ramos Glória JC, Aguiar Tavano KT. Efficacy of red and infrared lasers in treatment of temporomandibular disorders--a double-blind, randomized, parallel clinical trial. *Cranio*. 2014;32(1):51-6.
21. Miller DL, Smith NB, Bailey MR, Czarnota GJ, Hynynen K, Makin IR. Overview of therapeutic ultrasound applications and safety considerations. *J Ultrasound Med*. 2012;31(4):623-34.
22. Rai S, Ranjan V, Misra D, Panjwani S. Management of myofascial pain by therapeutic ultrasound and transcutaneous electrical nerve stimulation: a comparative study. *Eur J Dent*. 2016;10(1):46-53.
23. Monaco A, Sgolastra F, Ciarrocchi I, Cattaneo R. Effects of transcutaneous electrical nervous stimulation on electromyographic and kinesiographic activity of patients with temporomandibular disorders: a placebo-controlled study. *J Electromyogr Kinesiol*. 2012;22(3):463-8.
24. Seifi M, Ebadifar A, Kabiri S, Badiie MR, Abdolazimi Z, Amdjadi P. Comparative effectiveness of low level laser therapy and transcutaneous electric nerve stimulation on temporomandibular joint disorders. *J Lasers Med Sci*. 2017;8(1):S27-31.
25. Tuncer AB, Ergun N, Tuncer AH, Karahan S. Effectiveness of manual therapy and home physical therapy in patients with temporomandibular disorders: a randomized controlled trial. *J Bodyw Mov Ther*. 2013;17(3):302-8.
26. El Hage Y, Politti F, Sousa DF, Herpich CM, Gloria IP, Gomes CA, et al. Effect of mandibular mobilization on electromyographic signals in muscles of mastication and static balance in individuals with temporomandibular disorder: study protocol for a randomized controlled trial. *Trials*. 2013;14:316.
27. Kalamir A, Bonello R, Graham P, Vitiello AL, Pollard H. Intraoral myofascial therapy for chronic myogenous temporomandibular disorder: a randomized controlled trial. *J Manipulative Physiol Ther*. 2012;35(1):26-37.
28. Amaral AP, Politti F, Hage YE, Arruda EE, Amorin CF, Biasotto-Gonzalez DA. Immediate effect of nonspecific mandibular mobilization on postural control in subjects with temporomandibular disorder: a single-blind, randomized, controlled clinical trial. *Rev Bras Fisioter*. 2013;17(2):121-7.
29. Moraes AR, Sanches ML, Ribeiro EC, Guimarães AS. Therapeutic exercises for the control of temporomandibular disorders. *Dental Press J Orthod*. 2013;18(5):134-9.
30. Furto ES, Cleland JA, Whitman JM, Olson KA. Manual physical therapy interventions and exercise for patients with temporomandibular disorders. *Cranio*. 2006;24(4):283-91.
31. Ucar M, Sarp Ü, Koca İ, Eroğlu S, Yetişgin A, Tutoglu A, Boyacı. Effectiveness of a home exercise program in combination with ultrasound therapy for temporomandibular joint disorders. *J Phys Ther Sci*. 2014;26(12):1847-9.
32. Story WP, Durham J, Al-Baghdadi M, Steele J, Araujo-Soares V. Self-management in temporomandibular disorders: a systematic review of behavioural components. *J Oral Rehabil*. 2016;43(10):759-70.
33. Itoh K, Asai S, Ohyabu H, Imai K, Kitakoji H. Effects of trigger point acupuncture treatment on temporomandibular disorders: a preliminary randomized clinical trial. *J Acupunct Meridian Stud*. 2012;5(2):57-62.
34. Kawakita K, Okada K. Acupuncture therapy: mechanism of action, efficacy, and safety: a potential intervention for psychogenic disorders? *Biopsychosoc Med*. 2014;8:4.
35. Oliveira RF, Silva CV, Cersosimo MC, Borsatto MC, Freitas PM. Laser therapy on points of acupuncture: are there benefits in dentistry? *J Photochem Photobiol B*. 2015;151:76-82.
36. Vicente-Barrero M, Yu-Lu SL, Zhang B, Bocanegra-Pérez S, Durán-Moreno D, López-Márquez A, et al. The efficacy of acupuncture and decompression splints in the treatment of temporomandibular joint pain-dysfunction syndrome. *Med Oral Patol Oral Cir Bucal*. 2012;17(6):e1028-33.
37. Garbelotti TO, Turci AM, Serigato JMVA, Pizzol KEDC, Franco-Micheloni AL. Effectiveness of acupuncture for temporomandibular disorders and associated symptoms. *Rev Dor*. 2016;17(3):223-7.
38. Wu JY, Zhang C, Xu YP, Yu YY, Peng L, Leng WD, et al. Acupuncture therapy in the management of the clinical outcomes for temporomandibular disorders: a PRISMA-compliant meta-analysis. *Medicine (Baltimore)*. 2017;96(9):e6064.
39. Cascos-Romero J, Vázquez-Delgado E, Vázquez-Rodríguez E, Gay-Escoda C. The use of tricyclic antidepressants in the treatment of temporomandibular joint disorders: systematic review of the literature of the last 20 years. *Med Oral Patol Oral Cir Bucal*. 2009;14(1):E3-7.
40. Bal Kucuk B, Tolunay Kaya S, Karagoz Motro P, Oral K. Pharmacotherapeutic agents used in temporomandibular disorders. 2014;20:740-3.
41. Rezazadeh F, Hajian K, Shahidi S, Piroozi S. Comparison of the effects of transcutaneous electrical nerve stimulation and low-level laser therapy on drug-resistant temporomandibular disorders. *J Dent (Shiraz)*. 2017;18(3):187-92.
42. Häggman-Henrikson B, Alstergren P, Davidson T, Högestätt ED, Östlund P, Tranæus S, et al. Pharmacological treatment of oro-facial pain – health technology assessment including a systematic review with network meta-analysis. *J Oral Rehabil*. 2017;44(10):800-26.
43. Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomized trials. *BMJ*. 2011;343:1-9.
44. Cavalcanti MF, Silva UH, Leal-Junior EC, Lopes-Martins RA, Marcos RL, Pallotta RC, et al. Comparative study of the physiotherapeutic and drug protocol and low-level laser irradiation in the treatment of pain associated with temporomandibular dysfunction. *Photomed Laser Surg*. 2016;34(12):652-6.
45. Vidor LP, Torre IL, Custódio de Souza IC, Fregni F, Caumo W. Analgesic and sedative effects of melatonin in temporomandibular disorders: a double-blind, randomized, parallel-group, placebo-controlled study. *J Pain Symptom Manage*. 2013;46(3):422-32.

46. Grillo CM, Canales GL, Wada RS, Alves MC, Barbosa CM, Berzin F, Sousa ML. Could acupuncture be useful in the treatment of temporomandibular dysfunction? *J Acupunct Meridian Stud.* 2015;8(4):192-9.
47. Ismail F, Demling A, Heßling K, Fink M, Stiesch-Scholz M. Short-term efficacy of physical therapy compared to splint therapy in treatment of arthrogenous TMD. *J Oral Rehabil.* 2007; 34(11):807-13.
48. Qvintus V, Suominen AL, Huttunen J, Raustia A, Ylöstalo P, Sipilä K. Efficacy of stabilisation splint treatment on facial pain – 1-year follow-up. *J Oral Rehabil.* 2015;42(6):439-46.
49. Huttunen J, Qvintus V, Suominen AL, Sipilä K. Role of psychosocial factors on treatment outcome of temporomandibular disorders. *Acta Odontol Scand.* 2019; 77(2):119-125.
50. Michelotti A, Iodice G, Vollaro S, Steenks MH, Farella M. Evaluation of the short-term effectiveness of education versus an occlusal splint for the treatment of myofascial pain of the jaw muscles. *J Am Dent Assoc.* 2012;143(1):47-53.
51. Niemelä K, Korpela M, Raustia A, Ylöstalo P, Sipilä K. Efficacy of stabilisation splint treatment on temporomandibular disorders. *J Oral Rehabil.* 2012;39(11):799-804.
52. Cuccia AM, Caradonna C, Annunziata V, Caradonna D. Osteopathic manual therapy versus conventional conservative therapy in the treatment of temporomandibular disorders: a randomized controlled trial. *J Bodyw Mov Ther.* 2010;14(2):179-84.
53. Mejersjö C, Wenneberg B. Diclofenac sodium and occlusal splint therapy in TMJ osteoarthritis: a randomized controlled trial. *J Oral Rehabil.* 2008;35(10):729-38.
54. Felício CM, Melchior MO, Silva MAMR. Effects of orofacial myofunctional therapy on temporomandibular disorders. *Cranio.* 2010;28(4):249-59. <http://dx.doi.org/10.1179/crn.2010.033>.
55. Carrasco TG, Mazzetto MO, Mazzetto RG, Mestriner Junior W. Low intensity laser therapy in temporomandibular disorder: a phase II double-blind study. *Cranio.* 2008;26(4):274–81.
56. Ahrari F, Madani AS, Ghafouri ZS, Tunér J. The efficacy of low-level laser therapy for the treatment of myogenous temporomandibular joint disorder. *Lasers Med Sci.* 2014;29(2):551-7.
57. Mazzetto MO, Hotta TH, Pizzo RC. Measurements of jaw movements and TMJ pain intensity in patients treated with GaAlAs laser. *Braz Dent J.* 2010;21(4):356-60.
58. Herpich CM, Leal-Junior ECP, Politti F, Paula Gomes CAF, Santos Glória IP, Souza Amaral MFR, et al. Intraoral photobiomodulation diminishes pain and improves functioning in women with temporomandibular disorder: a randomized, sham-controlled, double-blind clinical trial. *Lasers Med Sci.* 2019;1-7. <http://dx.doi.org/10.1007/s10103-019-02841-1>.
59. Pramod GV, Shashikanth M, Shambulingappa P, Lele S. Analgesic efficacy of diazepam and placebo in patients with temporomandibular disorders: a double blind randomized clinical trial. *Indian J Dent Res.* 2011;22(3):404-9.
60. Haviv Y, Rettman A, Aframian D, Sharav Y, Benoliel R. Myofascial pain: an open study on the pharmacotherapeutic response to stepped treatment with tricyclic antidepressants and gabapentin. *J Oral Facial Pain Headache.* 2015;29(2):144-51.
61. Ferreira AP, Costa DR, Oliveira AI, Carvalho EA, Conti PC, Costa YM, Bonjardim LR. Short-term transcutaneous electrical nerve stimulation reduces pain and improves the masticatory muscle activity in temporomandibular disorder patients: a randomized controlled trial. *J Appl Oral Sci.* 2017;25(2):112-20.
62. Fernández-Carnero J, La Touche R, Ortega-Santiago R, Galan-del-Rio F, Pesquera J, Ge HY, Fernández-de-Las-Peñas C. Short-term effects of dry needling of active myofascial trigger points in the masseter muscle in patients with temporomandibular disorders. *J Orofac Pain.* 2010;24(1):106-12.
63. Brochado FT, Jesus LH, Carrard VC, Freddo AL, Chaves KD, Martins MD, et al. Comparative effectiveness of photobiomodulation and manual therapy alone or combined in TMD patients: a randomized clinical trial. *Braz Oral Res.* 2018;32:1-12.
64. Borges RMM, Cardoso DS, Flores BC, Luz RD, Machado CR, Cerveira GP, et al. Effects of different photobiomodulation dosimetries on temporomandibular dysfunction: a randomized, double-blind, placebo-controlled clinical trial. *Lasers Med Sci.* 2018;33(9):1859-66.
65. Wright EF, North SL. Management and treatment of temporomandibular disorders: a clinical perspective. *J Man Manip Ther.* 2009;17(4):247-54.

Received: Oct 21, 2018

Accepted: Sep 30, 2019